β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖

β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway

目的探讨β-紫罗兰酮(β-Ionone,BI)通过调节核因子-κB(Nuclear factor kappa-B,NF-κB)对乳腺癌细胞增殖过程的抑制作用及其可能的机制。方法采用亚甲基蓝(Methylene blue,MB)法和MTT法测定人乳腺癌BT549细胞和MCF-7细胞活性,孔雀石绿磷酸盐法检测蛋白磷酸酶2A(Protein phosphatase 2A,PP2A)活性、免疫印迹法检测磷酸化P65(p-P65)(s536和s311)、PP2A(A、B和C)和磷酸化共济失调毛细血管扩张突变基因(Phosphorylation-ataxia telangiectasia-mutated gene,p-ATM)(s1981)蛋白水平。结果BI可明显抑制人乳腺癌BT549细胞和MCF-7细胞的增殖,且呈时间和剂量依赖性,差异具有统计学意义(P<0.01)。MCF-7细胞经BI处理后,NF-κB活性被显著抑制,表现为磷酸化P65(s536和s311)的蛋白水平显著降低,PP2A的蛋白水平升高,差异具有统计学意义(P<0.05)。此外,BI还显著地降低PP2A抑制剂冈田酸(Okadaic acid,OA)对MCF-7细胞中P65蛋白和ATM蛋白的磷酸化作用。结论该研究表明BI通过抑制NF-κB活性来抑制乳腺癌细胞的增殖,其机制可能是BI通过增加PP2A活性调节NF-κB通路。

Objective This article aimed to explore the inhibitory effect ofβ-ionone(BI)on the proliferation of breast cancer cells through the nuclear factor kappa-B(NF-κB)pathway and its possible mechanism.Methods The methylene blue assay and MTT assay were used to determine the viability of breast cancer cells.The malachite green phosphate assay was used to detect the activity of protein phosphatase 2A(PP2A).Western blot was used to detect the levels of phosphorylated P65(s534 and s311)(p-P65),PP2A(A,B and C),and phosphorylated ataxia telangiectasia mutant(p-ATM)(s1981)protein.Results BI could significantly inhibit the proliferation of human breast cancer BT549 cells and MCF-7 cells in a time-and dose-dependent manner,and the difference was statistically significant(P<0.01).After treated with BI,NF-κB activity was significantly inhibited in MCF-7 cells,as shown by a significant decrease in the level of phosphorylated P65(s311 and s534)protein and an increase in the level of PP2A protein,and the difference was statistically significant(P<0.05).In addition,BI also significantly reduced the phosphorylation of P65 protein and ATM protein in MCF-7 cells by the PP2A inhibitor-okada acid(OA).Conclusion This study shows that BI inhibits the proliferation of breast cancer cells by inhibiting NF-κB activity,and its mechanism may be achieved by increasing PP2A activity to regulate the NF-κB pathway.